Considerations in characterizing real‐world data relevance and quality for regulatory purposes: A commentary
Cynthia J. Girman(University of North Carolina at Chapel Hill), Nancy A Dreyer(IQVIA (United Kingdom)), Mary E. Ritchey(RTI Health Solutions), Wei Zhou(Broad Institute)
Cited by 40
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
The Metabolic Syndrome and 11-Year Risk of Incident Cardiovascular Disease in the Atherosclerosis Risk in Communities Study
|Diabetes Care|2005|1.1k
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Rapidly in Situ Forming Biodegradable Robust Hydrogels by Combining Stereocomplexation and Photopolymerization
|Journal of the American Chemical Society|2007|156
Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
|Journal of Thoracic Oncology|2016|156